Inactive Instrument

ImmunoGen, Inc.

Equities

IMGN

US45253H1014

Biotechnology & Medical Research

ImmunoGen, Inc. : Announces Webcast of Presentation at the 32nd Annual J.P. Morgan Healthcare Conference

January 06, 2014 at 10:01 pm IST

MarketScreener.com By

ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapies using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius, President and CEO, will present at the upcoming 32nd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for 8:00 am PT (11:00 am ET) on January 13, 2014.

A webcast of this presentation will be accessible live through the "Investor Information" section of the Company's website, www.immunogen.com; a replay of the presentation will be available at the same location for two weeks.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's ADC technology uses a tumor-targeting engineered antibody to deliver one of ImmunoGen's highly potent cancer-cell killing agents specifically to tumor cells; the Company has also developed antibodies with anticancer activity of their own. The most advanced compound with ImmunoGen's ADC technology is Roche's Kadcyla^®, which is marketed in the US by Genentech and is also gaining approvals internationally. Additional compounds are in clinical testing by ImmunoGen and through the Company's partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More information about ImmunoGen can be found at www.immunogen.com.

Kadcyla^® is a registered trademarks of Genentech, Inc., a member of the Roche Group.

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For Media:
The Yates Network
Barbara Yates, 781-258-6153

Latest news about ImmunoGen, Inc.

AbbVie CEO to Retire; COO Robert Michael Named Successor	21/02	MT
BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase	13/02	AN
Biopharma Credit Secures $51 Million Loan Repayment from US Biotech ImmunoGen	13/02	MT
ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P Global BMI Index	13/02	CI
ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P TMI Index	13/02	CI
ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P Biotechnology Select Industry Index	13/02	CI
Top Stories at Midday: Bezos Sells Nearly 12 Million Amazon Shares; Diamondback's $26 Billion Endeavor Energy Deal; Citigroup's Risk Management Procedures Rebuked; AbbVie Buys ImmunoGen	12/02	MT
AbbVie Completes $10.1 Billion Acquisition of ImmunoGen, Lowers Q1 Adjusted EPS Guidance	12/02	MT
AbbVie Acquires ImmunoGen for $31.26 per Share	12/02	MT
AbbVie: acquisition of ImmunoGen finalized	12/02	CF
Immunogen, Inc. Announces Board Changes	12/02	CI
ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index	12/02	CI
AbbVie Inc. completed the acquisition of ImmunoGen, Inc. from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc., State Street Corporation, The Vanguard Group, Inc. and others.	12/02	CI
ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Biotechnology Index	09/02	CI
ImmunoGen Insider Sold Shares Worth $352,391, According to a Recent SEC Filing	07/02	MT
ImmunoGen Insider Sold Shares Worth $588,733, According to a Recent SEC Filing	07/02	MT
AbbVie 4Q Sales Lower as Himura Revenue Sinks	02/02	DJ
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals	02/02	RE
Immunogen Insider Sold Shares Worth $5,562,450, According to a Recent SEC Filing	19/01	MT
Drugmakers kick off industry conference with two cancer deals	08/01	RE
J&J to buy cancer therapy developer Ambrx for $2 bln	08/01	RE
2023 highlights of the stock market year	21/12
BioMarin settles with Elliott, adds 3 independent directors	21/12	RE
ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH	10/12	CI
Health Care Climbs as Deal Wave Seen Continuing -- Health Care Roundup	09/12	DJ

Chart ImmunoGen, Inc.

Duration

Period

More charts

Company Profile

ImmunoGen, Inc. is a commercial-stage biotechnology company. The Company is focused on developing and commercializing of antibody- drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its ELAHERE (Mirvetuximab Soravtansine) is a first-in-class ADC targeting folate receptor alpha (FRa), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Its Pivekimab sunirine (PVEK), is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. The Company is advancing PVEK in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).

Sector

Biotechnology & Medical Research

Calendar

26/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+25.83%	47.96B
LONZA GROUP AG	+45.38%	41.47B
IQVIA HOLDINGS INC.	+0.69%	42.45B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	31.6B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.56B
MEDPACE HOLDINGS, INC.	+49.18%	14.14B
BIO-TECHNE CORPORATION	+3.45%	12.58B

Other Biotechnology & Medical Research